Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth.

Read more at prnewswire.com